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Background: Optimal starting point for antiretroviral treatment (ART) has been uncertain.
Methods: Parallel group, single blind, randomised controlled study of adult HIV positive patients consulting at the
Protestant Hospital, Ngaoundere, Cameroon in 2007-8. Simple randomisation of patients in WHO clinical stage 1-2
to start of ART early or deferred, i.e. when CD4 counts dropped below 350 versus 250 cells/mm3, or when they
reached clinical stage 3-4. Clinical follow-up every three months were offered for all patients. Main outcomes were
clinical stage, CD4 differences and mortality. Of 424 consulting patients, most were excluded, mainly because they
were already in WHO stage 3-4. Forty-four patients were randomised.
Results: In the ‘early’ group two patients died and five were lost to follow-up. In the ‘deferred’ group, six patients
died and nine were lost to follow-up (Hazard ratio for death by early compared to deferred treatment 0.26, 95%
confidence interval 0.05-1.29). Of the patients lost to follow-up, three patients in the ‘early’ group and four patients
in the ‘deferred’ group were known to be alive when the study ended. Fourteen patients in the early group and 11
in the deferred group started ART. Twenty-two patients were evaluated clinically six to seven months after the study
period was terminated. Except for one patient with AIDS, these were all still in clinical stage 1-2.
Conclusions: In our small sample, relative risk for death did not differ significantly, but deferred treatment seemed
to carry no increased survival or other clinical advantage. During the study period, other studies made WHO
change its guidelines to conform to our early treatment. The tendency in our study lends support to this policy.
Trial registration: ISRCTN22114173Background
With the 2010 and 2013 guidelines, WHO recommen-
ded earlier initiation of antiretroviral treatment (ART)
than in previous guidelines [1]. Evidence for a beneficial
effect of earlier start of treatment was shown first in
Western countries [2-4]. Later on, studies from African
countries and Haiti have supported this [5-8]. Population
effects pointed in the same direction [9-11]. Randomised
studies are few and there has recently been a call for
more research about when to start ART in Africa [12].
One reason we started our study in 2007, was precisely* Correspondence: knut.holtedahl@uit.no
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reproduction in any medium, provided the orbecause our clinical impression from around 2003 was
that ART was initiated too late. Other authors had argued
that WHO patients with clinical stage 3 and 4 should ini-
tiate treatment [13]. ART became accessible in Cameroon
around 2002-4, both in terms of drug supply and through
a sharp decline in prices, ending with free distribution of
some drugs in large parts of the country from around
2005. CD4 counts have been accessible more or less con-
tinuously from 2005, but are usually free of charge only
during campaigns and for pregnant women. Recommen-
dations for low income settings before 2010 were to initi-
ate treatment when a patient’s CD4 count dropped below
200 cells/mm3. National guidelines were in agreement
with this. We report results from our study, which to
some extent answered the original question of when to
start, but also revealed some unexpected experiences.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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All new cases of adult treatment-naïve HIV-positive pa-
tients diagnosed between 15 March 2007 and 31 Decem-
ber 2008 at the Protestant Hospital in Ngaoundere, a
town of 300 000 inhabitants in Northern Cameroon, were
considered eligible for the study. They were randomised
to initiating treatment with CD4 counts of either <250
or <350 cells/mm3, or when their condition after random-
isation progressed to WHO clinical stage 3 or 4. Exclusion
criteria were:
1. Patient fulfilled current local indications for
immediate treatment: CD4 < 250 cells/mm3 or
WHO clinical stage 3 or 4.
2. CD4 was currently >450 cells/mm3. This was
because the patient would probably not start ART
during the first year.
3. Age less than 16 years.
Enrolled patients who did not start treatment right
after randomisation were scheduled to have clinical and
CD4 controls free of charge every three months. After
start of treatment, control of CD4 was offered every six
months. Outcome measures were WHO clinical stage,
mortality, changes in CD4 and weight maintenance. Be-
cause patients were to be recruited in WHO stage I-II,
we did not expect many deaths during the three and a
half years our study was meant to last. Power calcula-
tions therefore were made based on substitute outcomes,
i.e. differences in cd4 values and weight loss. A mean
group difference in final CD4 value of 100 cells/mm3
and a mean weight loss difference of two kilos were con-
sidered clinically important. In our calculations we used
anticipated cd4 values of 400 and 300 cells/mm3 and a
standard deviation of 100, and for weight loss 5 ± 2 kg
and 3 ± 1.5 kg. To show such differences, calculations
with significance level 5% and a statistical power 90% in
both cases suggested that 21 patients in each group were
needed [14].
The choice of drugs for ART in Ngaoundere was very
limited. In practice almost all patients in 2007-8 received
a one drug combination of lamivudine, stavudine and
nevirapine. The exception was patients previously trea-
ted for Tb, who received efivarenz instead of nevirapine;
three patients in our study. From 2008-9 serious stavudine
side effects caused a gradual change of the three-drug pill
to one where stavudine was replaced by zidovudine. This
was the same for both groups. Cotrimoxazole was given
routinely to all patients receiving ART, and also to other
patients coming for routine follow-up.
Patients who started ART were informed about the rea-
son for this, either cd4 level, WHO clinical stage, or both.
The study was scheduled to follow patients at least
until the end of 2010. We terminated our study in July2010, six months before planned, because both the WHO
and the Cameroonian recommendations had changed
during the preceding months, and the changes were in ac-
cordance with our early start of treatment. We then ac-
tively searched for the deferred therapy patients who did
not present themselves according to their follow-up plan.
Postal street addresses do not exist in Ngaoundere, but
some of the patients could be contacted by mobile phone.
During the first months of 2011 we were able to carry out
the planned independent clinical evaluation for half of the
original patients. It took some time to find the where-
abouts of all patients, and censoring as dead, lost-to-
follow-up or having been clinically evaluated was done
with 30 June 2011 as the ultimate date.
Randomisation and masking
The patients gave written, informed consent after clinical
examination by a medical doctor. Printed information
in French, Fulfulde and Haoussa (English translation,
Additional file 1) was prepared and either read by the pa-
tient or read aloud in the preferred language when
the patient was illiterate. After consent, randomisation
was performed by opening the top envelope in a stack
containing numbers prepared from a table of consecutive
random numbers. Randomisation was thus open to the
study group, but blinded for the patients. They were told
before signing that they would receive ART when the
follow-up showed it was time to start treatment.
The final evaluation in January-February 2011 was per-
formed by one of the authors (ZB), a specialist in infec-
tious diseases, who had recently been employed by the
hospital and had no previous knowledge of the patients.
Thus, he was blinded to each patient’s group belonging.
Statistics
The Kaplan-Meier plot was applied to show the esti-
mated survival functions for the two treatment groups.
We used the Cox Proportional Hazards Model to calcu-
late the hazard ratio for death according to treatment,
with a corresponding 95% confidence interval. Intention-
to-treat analyses were performed.
Role of the funding source
The authors designed and performed the study without
any interference from the two funding sources.
Results
Between April 2007 and November 2008, 424 HIV posi-
tive patients consulted at the Protestant Hospital. Most
patients fulfilled one or more of the exclusion criteria.
They therefore did not go through the randomisation
procedure, and most of them started ART within a few
weeks. CD4 was measured in 381 patients. Mean values
were 174 cells/mm3 for 227 females and 138 cells/mm3
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study, 28 females and 16 males, with a mean age of 31
and 36 years, respectively. Five patients were pregnant
when they were diagnosed and recruited into the study,
they did not previously know they had seroconverted
and were ART-naïve like the other patients. Baseline char-
acteristics are shown in Table 1. Exclusions are shown in
Figure 1. During follow-up, patients had from zero to
seven visits with CD4 count, more regularly after initiated
ART therapy because this usually meant monthly visits
with renewal of drug supply.
Fourteen patients randomised to early treatment star-
ted ART, 13 because of CD4 < 350 cells/mm3, the last
patient erroneously because an attack of herpes zoster
was considered as stage 3. This patient later died. Eleven
patients randomized to deferred treatment started ART,
seven of them because they went below the threshold
of <250 cells/mm3, four because they reached WHO stage
3. Two females randomised to early treatment, and four
females and two males randomised to deferred treatment,
died. Of the eight dead patients, one ‘early’ and three ’de-
ferred’ patients had not started ART when they died 3Table 1 Baseline data, randomised patients (N = 44)
Characteristic Early treatment
cd4+ <350
cells/mm3 (N = 21)
Delayed treatment
cd4 + < 250
cells/mm3 (N = 23)
Age in years, mean (median) 33 (30) 33 (32)
Females 12 16
Males 9 7
Education (N = 41)
No schooling 5 7
1-4 years of school 3 9
5-8 years of school 6 2
9+ years of education 6 3
Living with partner(s)
or alone (N = 42)
With partner 15 9
Alone 5 13
Pregnant 1 4
WHO stage 1 15 13






351 (360) 340 (337)
Body mass index, mean
(N = 7 + 5)
22 · 9 20 · 4
Weight in kilos, mean
(N = 8 + 8)
63 · 2 57 · 8
Hemoglobin concentration,
g/dl, mean (N = 14 + 18)
13 · 2 12 · 2to13 months after randomisation. The other four died
from 9-39 months after randomisation and 3-39 months
after ART had been started. Figure 2 suggests an improved
survival in the early treatment group, although not signifi-
cant in such a small sample (HR = 0.26, 95% CI 0.05-1.29).
Twenty-two patients went through the planned clinical
evaluation at the end of the trial. One patient in the
deferred group had AIDS, one in the early group was
in WHO stage 2, the twenty others were asymptom-
atic (Table 2). Mean CD4 in the ‘early’ group was 556
and in the ‘deferred’ group 382 cells/mm3, this differ-
ence is not significant.
Of the 14 patients lost to follow-up, three patients ran-
domised to early treatment and one to deferred treat-
ment moved to other towns, but some had occasional
telephone contact with the hospital. Patients from dis-
tant locations were offered travel money if they would
come to the final evaluation, but only one came. Vain ef-
forts were also made to have patients who had moved
inform us of their CD4 values taken elsewhere. Six of
the eight dead patients never had any CD4 follow-up,
and so was the case for three “early” and four “deferred”
patients lost to follow-up. The average BMI for the eval-
uated patients was similar for the two groups. Of the
dead patients, two had no schooling, four had 1-4 years
and two had 5-8 years of schooling.
Discussion and conclusions
Our study had a similar design as the Haitian study by
Severe et al [6], who started their study in 2005 and had
AIDS as their clinical exclusion criterion. When our study
started two years later, the CD4 criteria in Cameroon
followed WHO and national guidelines, with ART-start
when CD4 dropped below 200 cells/mm3. However, it had
become common to start treatment for patients in WHO
clinical stage III. At that time in Cameroon, it therefore
seemed unethical to expose stage III patients to deferred
treatment, and it turned out that a majority of potential
study patients had to be excluded because of this. With
few patients and incomplete follow-up, our results are
much less clear than the Haiti study, but their ten-
dency is the same. Deferred treatment seemed to carry no
increased survival or other clinical advantage. Sensitivity
analyses were performed where all patients lost to follow-
up and not known to be alive were counted as dead,
and with all patients lost to follow-up counted as alive,
but these analyses did not change conclusions (HR 0.42
(95% CI 0.15-1.22), and HR 0.33 (95% CI 0.07-1.66)),
respectively. Counting the evaluated patient with AIDS
among the dead gave only minimal changes. With few
studies adding to current evidence, we think our study
tells something about existing practical possibilities of
HIV therapy and follow-up, which are probably common
to many places in Africa.
424 hiv positive patients consulting:
252 females, 172 males
380 patients were excluded
18 had WHO stage 4 (aids)
273 had WHO stage 3
Of patients with WHO stage 1-2:
1 had cd4+ >450 cells/mm3 
72 had cd4+ <250 cells/mm3
10 had no cd4+ measurement
2 had started ARV
3 were erroneously classified WHO stage 3
1 was erroneously excluded because of 
pregnancy
21 patients Early treatment 
cd4+ <350 cells/mm3
23 patients Deferred treatment 
cd4+ < 250 cells/mm3
Simple randomisation
14 patients clinically evaluated 8 patients clinically evaluated
2 patients dead
5 lost to follow-up, 
3 known to be alive
6 patients dead
9 lost to follow-up,
4 known to be alive
Figure 1 Exclusions, inclusions and evaluation.
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came for evaluation were among the least sick, but it is
striking and encouraging that almost all were asymp-
tomatic. This is in agreement with our clinical impres-
sion that patients who come regularly for their ART drugs
in most cases improve clinically and remain well. Also,
patients coming regularly to controls and who have a rela-
tively high CD4 value usually avoid serious clinical deteri-
oration before ART can be started. This is in spite of the
limited local therapeutic offer of one standard ART com-
bination and one available second line alternative. In
Cameroon, scale-up of ART has been shown to be associ-
ated with increased drug resistance mutations [15], and
resistance monitoring may be the next priority after CD4
access [16]. Routine measuring of viral load seems to be alesser priority [17,18]. In 2013, consolidated WHO guide-
lines have recommended early start of ART on an even
broader base [1].
Median CD4 and BMI were slightly lower at base-
line for the deferred group, which had relatively more
females. The difference may have contributed to the
higher number of dead or lost to follow-up, but we
think the deferred treatment was more important. It
may be worth noting that all the dead patients had
little or no schooling.
To get an idea about natural CD4 decline without treat-
ment, and thus about the lead time bias for the deferred
treatment patients, we had foreseen an auxiliary study of
patients who had at least one repeat measure of CD4 be-
fore ART became common. For this purpose, we went
Figure 2 Kaplan-Meier plot with estimated survival functions for the two treatment groups.
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ing the years 2003-7 at an HIV clinic in the region. We
found 154 patients with repeat measures before any writ-
ten signs of prescriptions of ART drugs. However, many




-but known to be alive when project ended
Started ARV
Alive with ARV
Number of days from diagnosis to start of ARV, mean (median) (N = 12 + 8)
Not started ARV
Alive without having started ARV
Number of days from diagnosis to censoring, mean (median)
Evaluated patients (N = 22)
Number of patients evaluated (Females + Males)





cd4+ count, cells/mm3, mean (median) (N = 14 + 7)
Body mass index (BMI), mean (N = 14 + 8)
Weight in kilos, mean (N = 14 + 8)
Haemoglobin concentration, g/dl, mean (N = 14 + 7)suggested that they had been treated in spite of no men-
tion of this in the medical record, and we have not used
these data. Without such data and also missing CD4 data
for several patients, differences in mean CD4 values in the
two groups are difficult to interpret. In the Ivory CoastEarly treatment cd4+ <350
cells/mm3 (N = 21)
Delayed treatment cd4 + < 250






390 (164) 340 (276)
7 12
4 3
857 (808) 585 (562)
14 (8 + 6) 8 (6 + 2)




556 (547) 382 (319)
23 · 6 22 · 8
65 · 2 62 · 6
12 · 7 11 · 2
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values of less than 350 cells/mm3 within seven years after
seroconversion [19].
Strength and limitations of the study
The randomised design is a strong element in our study.
There are several weak points, mainly the low number
of patients and the incomplete follow-up, resulting in
unclear answers to our main questions. The setting
is realistic and probably not very different from many
African hospitals in towns and villages. The hospital
is relatively well staffed with competent doctors and
skilled nurses.
Comparison with existing literature
While we were performing our study, other authors
added to the evidence that earlier ART start might be
beneficial [20,21], both for survival [3] and for reducing
morbidity and transmission [9]. Loss to follow-up was a
problem in our study, and has been shown to be most
important between HIV testing and CD4 testing [22,23].
Delayed first consultation after diagnosis was reduced
through decentralized activities in a Cameroonian study
[24]. A large study from Kenya, Uganda and Zambia
confirmed that many aspects of ART care could poten-
tially be carried out safely and effectively at smaller,
lower complexity facilities with less-specialised person-
nel [25]. Our patients had to wait for their CD4 results,
and point-of-care cell counts have been shown to reduce
loss to follow-up in some settings [26]. When comparing
cost-effectiveness of CD4 cell count and WHO clinical
staging to guide initiation of ART, CD4 cell count was
superior in a study with data from sub-Saharan Africa
[27] and in a study from Uganda [28].
Risk of HIV infection in Africa has been shown to
be associated with a low educational level [29], and
more than half of our patients had less than five years of
schooling.
Implications for clinical practice and research
Patients with HIV may benefit from ART while they are
still asymptomatic. Cytometric CD4 testing is a good
and cheap method for evaluating optimal starting point
for ART, and more studies are needed to further docu-
ment recommended thresholds in WHO guidelines [5].
In resource-limited settings, competent HIV services need
to be decentralised to make appropriate follow-up avail-
able in a realistic way. General education is a necessity in
modern society, among other things to help people under-
stand how to avoid the virus and how to get follow-up if
seroconversion occurs. Large, well-financed research pro-
jects often give the best answers to how to treat HIV, but
smaller local clinical studies are also needed to increase
the evidence base and implement new knowledge.Ethical approval
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